bd 1047 has been researched along with neuropeptide y in 1 studies
| Studies (bd 1047) | Trials (bd 1047) | Recent Studies (post-2010) (bd 1047) | Studies (neuropeptide y) | Trials (neuropeptide y) | Recent Studies (post-2010) (neuropeptide y) |
|---|---|---|---|---|---|
| 118 | 0 | 54 | 10,663 | 152 | 2,269 |
| Protein | Taxonomy | bd 1047 (IC50) | neuropeptide y (IC50) |
|---|---|---|---|
| Neuropeptide Y receptor type 1 | Homo sapiens (human) | 0.0014 | |
| Neuropeptide Y receptor type 2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clinckers, R; Ebinger, G; Meurs, A; Michotte, Y; Smolders, I | 1 |
1 other study(ies) available for bd 1047 and neuropeptide y
| Article | Year |
|---|---|
Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y.
Topics: Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Epilepsy; Ethylenediamines; Hippocampus; Male; Microdialysis; Neuropeptide Y; Pilocarpine; Rats; Rats, Wistar; Receptors, sigma; Remoxipride; Severity of Illness Index; Sigma-1 Receptor; Time Factors | 2007 |